CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH Rb Deletion in Mouse Mammary Progenitors Induces Luminal-B or Basal-Like/EMT Tumor Subtypes Depending on p53 Status Here, scientists reported that deletion of Rb (retinoblastoma) alone or together with its relative p107 in mouse mammary stem/bipotent progenitor cells induced focal acinar hyperplasia with squamous metaplasia. [J Clin Invest] Telomerase-Immortalized Human Mammary Stem/Progenitor Cells with Ability to Self-Renew and Differentiate Researchers presented evidence that normal and human telomerase reverse transcriptase-immortalized human mammary epithelial cells isolated and maintained in Dana-Farber Cancer Institute 1 medium retain a fraction with progenitor cell properties. [ Proc Natl Acad Sci USA] Reprogramming Human Cancer Cells in the Mouse Mammary Gland Here, investigators reported that human embryonal carcinoma cells proliferate and produce differentiated mammary epithelial cell progeny when mixed with mouse mammary epithelial cells and inoculated into the epithelium-free mammary fat pads of athymic nude mice. [Cancer Res] The Relationship Between Terminal Functionalization and Molecular Weight of a Gene Delivery Polymer and Transfection Efficacy in Mammary Epithelial 2-D Cultures and 3-D Organotypic Cultures Non-viral gene delivery vectors were developed for efficient gene transfer to hard-to-transfect mouse mammary epithelial cells. Ten modified versions of the same base poly(beta-amino ester), poly(1,4-butanediol diacrylate-co-5-amino-1-pentanol), were tested in both traditional 2-D monolayer and in 3-D organotypic cultures. [Biomaterials] Rb Inactivation Accelerates Neoplastic Growth and Substitutes for Recurrent Amplification of cIAP1, cIAP2 and Yap1 in Sporadic Mammary Carcinoma Associated with p53 Deficiency Researchers used newly generated MMTV-Cre105Ayn mice to inactivate p53 and/or Rb strictly in the mammary epithelium, and to determine recurrent genomic changes associated with deficiencies of these genes. [Oncogene] ZNF217, a Candidate Breast Cancer Oncogene Amplified at 20q13, Regulates Expression of the ErbB3 Receptor Tyrosine Kinase in Breast Cancer Cells In this study scientists showed that the ZNF217 transcription factor, amplified at 20q13 in ~20% of breast tumors, regulates ErbB3 expression. [Oncogene] Glycodelin Expression Associates with Differential Tumour Phenotype and Outcome in Sporadic and Familial Non-BRCA1/2 Breast Cancer Patients To investigate the association of glycodelin with clinicopathological features of breast cancer and outcome of patients, researchers evaluated the protein expression of glycodelin in a large series of breast tumours. [Breast Cancer Res Treat] Cacalol, a Natural Sesquiterpene, Induces Apoptosis in Breast Cancer Cells by Modulating Akt-SREBP-FAS Signaling Pathway In this report, investigators demonstrated that cacalol has strong anti-proliferation effect on breast cancer cells and induces apoptosis by activating a pro-apoptotic pathway. [Breast Cancer Res Treat] Plasmonics Nanoprobes: Detection of Single-Nucleotide Polymorphisms in the Breast Cancer BRCA1 Gene This paper described the application of plasmonics-based nanoprobes that combine the modulation of the plasmonics effect to change the surface-enhanced Raman scattering of a Raman label and the specificity of a DNA hairpin loop sequence to recognize and discriminate a variety of molecular target sequences. [Anal Bioanal Chem] Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis Scientists demonstrated that both ferroportin and hepcidin are expressed in cultured human breast epithelial cells and that hepcidin regulates ferroportin in these cells. [Sci Transl Med] CLINICAL RESEARCH Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor-Positive, Metastatic Carcinoma of the Breast in Premenopausal Women The purpose of this study was to explore the antitumor activity of the aromatase inhibitor, anastrozole, in the treatment of premenopausal women with hormone receptor-positive, metastatic breast cancer who have been rendered functionally postmenopausal with the use of the luteinizing hormone-releasing hormone agonist, goserelin. [J Clin Oncol] Breast Cancer DNA Methylation Profiles Are Associated with Tumor Size and Alcohol and Folate Intake Using primary breast tumors from 162 (American Joint Committee on Cancer stage I-IV) women from the Kaiser Division of Research Pathways Study and the Illumina GoldenGate methylation bead-array platform, researchers measured 1,413 autosomal CpG loci associated with 773 cancer-related genes and validated select CpG loci with Sequenom EpiTYPER. [PLoS Genet]
|
|
POLICY NEWS New £50 Million Cancer Drug Money Unveiled The government has announced an emergency fund of £50 million to pay for drugs for cancer patients that have been ruled out by the drugs regulator the National Institute for Health and Clinical Excellence. [Department of Health, United Kingdom] Human Genetics Commission Sets New Standards for Direct-to-Consumer Genetic Tests The Common Framework of Principles for direct-to-consumer genetic testing services, published by the Human Genetics Commission, aims to ensure that people who choose to buy genetic tests themselves can have confidence that the companies selling them follow basic principles of consent, data protection, truth in marketing, scientific rigor and balanced interpretation. [Human Genetics Commission, United Kingdom] MHRA Business Plan 2010 and Corporate Plan 2010-15 Published The MHRA gained ministerial agreement for the Agency’s Business Plan 2010 and the Corporate Plan 2010-15. [Medicines and Healthcare Products Regulatory Agency, United Kingdom] Regulation of Advanced Therapy Medicinal Products in the UK The statutory instrument for implementing the UK’s requirements under the hospital exemption scheme (The Medicines for Human Use (Advanced Therapy Medicinal Products and Miscellaneous Amendments) Regulations 2010) was laid in Parliament on 26 July 2010. [Medicines and Healthcare Products Regulatory Agency, United Kingdom] Risk Evaluation and Mitigation Strategy (REMS) Public Meeting The Food and Drug Administration announced a 2-day public meeting to obtain input on issues and challenges associated with the development and implementation of risk evaluation and mitigation strategies for drugs. An archived webcast of the meeting is available. [Food and Drug Administration, United States] ASTRO Publishes Whole Breast Irradiation Guidelines The American Society for Radiation Oncology (ASTRO) has released evidence-based guidelines to define appropriate fractionation of whole breast irradiation (WBI), finding that hypofractionated WBI is effective for many patients with early-stage breast cancer. [American Society for Radiation Oncology, United States] More Funding Needed For Breast, Cervical Cancer Detection Program, Advocates Say During an event to mark its 20th anniversary, advocates of the National Breast and Cervical Cancer Early Detection Program expressed frustration that the program has not been extended to more low-income women and urged Congress to increase funding. [Centers for Disease Control and Prevention, United States] NSF Funding Request Faring Well in Congress While the 2011 budget requests of other U.S. research agencies are struggling to stay afloat in choppy fiscal seas, so far National Science Foundation’s (NSF) is sailing through Congress largely intact. [National Science Foundation, United States] Senate Spending Panel Approves $1 Billion Boost for NIH A Senate subcommittee matched President Barack Obama’s request for a $1 billion increase in 2011 for the National Institutes of Health (NIH). That raise would bring the agency’s total budget to $32 billion, or 3.5% above the 2010 level, according to a statement from the Senate appropriations labor, health, and human services subcommittee. [National Institutes of Health, United States] NIH Takes on New Role in Fight Against Rare Diseases A government program focusing on rare diseases, the Therapeutics for Rare and Neglected Diseases (TRND) program, has launched five pilot projects that are taking the National Institutes of Health in a new direction: developing drugs. TRND will work together with scientists, advocates and others to do the required research and testing on drugs before a compound can be tried in humans in a clinical trial. [National Institutes of Health, United States] National Human Genome Research Institute; Notice of Closed Meeting (Doc. 2010-18627) [National Institutes of Health, United States] National Cancer Institute; Notice of Closed Meetings [National Institutes of Health, United States] National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting [National Institutes of Health, United States] Correction of Major Programmatic Priorities for RFA-HL-11-025 (R01); “New Strategies for Growing 3D Tissues” (NOT-HL-11-115) [National Institutes of Health, United States] Agency Information Collection Activities: Proposed Collection; Comment Request [Agency for Healthcare Research and Quality, United States]
|
|
EVENTS (Listed by Date) Select Biosciences 3rd Annual Stem Cells Europe Conference August 24-25, 2010 Edinburgh, Scotland Select Biosciences Inaugural Cellular Therapy Summit August 24-25, 2010 Edinburgh, Scotland Stem Cells USA & Regenerative Medicine Congress 2010 September 13-15, 2010 Philadelphia, United States 15th Congress of the European Society of Surgical Oncology (ESSO) September 15-17, 2010 Bordeaux, France 2010 World Cancer Congress August 18-21, 2010 Shenzhen, China Cellular Therapy of Cancer Symposium – ATTACK Project Meeting September 24-27, 2010 Montpellier, France NEW Expert Perspectives: Integrating New Data into Best Practices for Breast Cancer October 1, 2010 National Harbor, United States 2010 Breast Cancer Symposium October 1-3, 2010 Washington, DC, United States 2nd International Inflammatory Breast Cancer Conference October 6-7, 2010 Marseille, France 35th European Society for Medical Oncology (ESMO) Congress October 8-12, 2010 Milan, Italy International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy October 18-19, 2010 West Lafayette, United States 16th World Congress of the International Society of Senology October 20-22, 2010 Valencia, Spain The 2010 American Institute for Cancer Research (AICR) Annual Research Conference on Food, Nutrition, Physical Activity & Cancer October 21-22, 2010 Washington, DC, United States MENA Oncology Conference October 22-23, 2010 Cairo, Egypt UAE Cancer Congress 2010 October 28-30, 2010 Dubai, United Arab Emirates 6th National Cancer Research Institute (NCRI) Conference November 7-10, 2010 Liverpool, United Kingdom NEW 22nd EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” November 16-19, 2010 Berlin, Germany 33rd Annual San Antonio Breast Cancer Symposium December 8-12, 2010 San Antonio, United States Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community. JOB OPPORTUNITIES Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News. Visit here to post your career opportunities.
Have we missed an important article or publication in Mammary Cell News? Click here to submit! |
| |
|